Clinical trials: Anti-Retroviral Agents
HIV
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals
Background: The immune system helps the body fight off disease. Most people infected with HIV cannot control the infection and need daily medicine.
- Trial name
- NCT03225118
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Coronary Heart Disease, Heart Failure
Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up
HIV-infection is associated not only with a reduced function of the immune system, but also linked with diseases of other organ systems, in particular with the heart.
- Conditions
- Coronary Heart Disease, Heart Failure, HIV, AIDS
- Trial name
- NCT01196273
- Testing
- Comprehensive non invasive cardiovascular examination
- Where
- 5 sites in Germany
- Volunteers
- 1,424 people
- Sponsor
- University Hospital, Essen
HIV Infections
Botswana TDF/FTC Oral HIV Prophylaxis Trial
This study tested whether taking a pill of tenofovir and emtricitabine (two antiretroviral medicines) was safe for sexually-active young adults in Botswana without HIV infection and whether it reduced their risk of getting an HIV…
- Trial name
- TDF2 (NCT00448669)
- Testing
- Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
- Where
- 2 sites in United States, Botswana
- Volunteers
- 1,219 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Drug Interaction
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
There are currently no published studies addressing drug-drug interactions (DDI) between masculinizing hormone therapy (MHT) and pre-exposure prophylaxis (PrEP) among transgender men (TGM).
- Trial name
- NCT04593680
- Testing
- Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
- Where
- Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections
A Study Comparing Two Forms of Didanosine in HIV-infected Patients
The purpose of this study is to see if the coated-capsule form of didanosine (ddI) is as safe and absorbed by the body as well as the chewable-tablet form of ddI. Didanosine (ddI) is an anti-HIV drug.
- Trial name
- NCT00002360
- Testing
- Didanosine
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Atherosclerosis, HIV Infections
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients
Rosuvastatin is a drug used to lower cholesterol, which also has other cardiovascular benefits. The goal of this project is to determine if rosuvastatin is effective at slowing the development of heart disease in people with HIV.
- Trial name
- NCT00673582
- Testing
- Rosuvastatin
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- University of British Columbia
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.
- Trial name
- NCT00002423
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV, Human Immunodeficiency Virus
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
- Trial name
- NCT02175680
- Testing
- PRO 140, Historical data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- CytoDyn, Inc.
HIV Infection
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first…
- Trial name
- CHAPAS-5 (NCT07792096)
- Testing
- Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)
- Volunteers
- 800 people
- Sponsor
- University College, London
HIV Infections, Hepatitis C
Effects of Ribavirin on Zidovudine or Stavudine
The purpose of this study is to see how treatment of hepatitis C (HCV) patients with ribavirin (RBV) affects the anti-HIV drugs stavudine (d4T) or zidovudine (ZDV).
- Trial name
- NCT00021632
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Background: Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV) can increase the amount of these blood thinners in the body.
- Trial name
- NCT03864406
- Testing
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections
Kaletra and Viread in Antiretroviral Naïve Patients
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to <50 copies/ml in antiretroviral naïve patients…
- Trial name
- NCT00679926
- Testing
- Once daily
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Oklahoma State University Center for Health Sciences
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV, Contraception
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
This study will evaluate the pharmacokinetic properties of rilpivirine and darunavir when used in combination with etonogestrel
- Trial name
- DRIVE-1 (NCT03589040)
- Testing
- Etonogestrel 68Mg Implant, rilpivirine, darunavir
- Where
- Uganda
- Volunteers
- 60 people
- Sponsor
- Makerere University
AIDS, Progressive Multifocal Leucoencephalopathy (PML)
Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?
Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous…
- Trial name
- NCT03969550
- Testing
- Measure of overall survival
- Volunteers
- 34 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
HIV
Exploratory Study on the Role of the Digestive Microbiota in Adults Living With HIV-1
Chronic immune activation present in aviremic people living with HIV under treatment promotes the onset of insulin resistance and metabolic syndrome, paving the way for the comorbidities that are currently the main causes of…
- Trial name
- MICRACTIVIH (NCT05724524)
- Testing
- Stool sample collection, Blood sample collection
- Where
- 2 sites in France
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
HIV
A Habit-formation and Gamification Intervention to Improve ART Adherence Among MSM HIV Patients in Mexico
In general, several studies show that adherence to antiretroviral therapy (ART) among men who have sex with men (MSM) is low. Yet, high adherence to ART is essential-not only to improve the quality of life and survival rates…
- Trial name
- FUERTES (NCT03410680)
- Testing
- FUERTES
- Where
- 3 sites in Mexico
- Volunteers
- 184 people
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
HIV
ARV Concentrations in Hair
Hair samples from subjects on antiretroviral therapy, both HIV- and HIV+ patients with HIV RNA <50copies/mL for >6 months will be analyzed to investigate the influence of race, hair color and hair treatment on ARV response.
- Trial name
- NCT02768779
- Testing
- Hair analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
The goal of Suubi+Adherence is to examine the impact and cost associated with an innovative intervention to increase adherence to HIV treatment for HIV-infected adolescents.
- Trial name
- NCT01790373
- Testing
- Suubi+Adherence, Bolstered Standard of Care
- Where
- 2 sites in United States, Uganda
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.